Amyloid-β peptides activate α1-adrenergic cardiovascular receptors

Hypertension

Volumn 62, Issue 5, 2013, Pages 966-972

  Haase, Nadine ^a   Herse, Florian ^a   Spallek, Bastian ^a   Haase, Hannelore ^b   Morano, Ingo ^b   Qadri, Fatimunnisa ^a   Szijártó, István A ^a   Rohm, Ilonka ^d   Yilmaz, Atilla ^d   Warrington, Junie P ^e   Ryan, Michael J ^e   Gollasch, Maik ^a   Müller, Dominik N ^a   Dechend, Ralf ^a,c   Wallukat, Gerd ^a  

^a Experimental and Clinical Research Center   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c HELIOS Klinikum Berlin   (Germany)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

1 adrenergic receptor; Alzheimer disease; amyloid peptides; hypertension; signal transduction; vasoconstriction

Indexed keywords

ALPHA 1 ADRENERGIC CARDIOVASCULAR RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[25-35]; ANTIBODY; AUTOANTIBODY; BISOPROLOL; CALCIUM; IRBESARTAN; PRAZOSIN; UNCLASSIFIED DRUG; URAPIDIL; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; AMYLOID BETA-PROTEIN (10-35); AMYLOID BETA-PROTEIN (25-35); PEPTIDE FRAGMENT; PIPERAZINE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; BLOOD VESSEL REACTIVITY; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CHO CELL; CHRONOTROPISM; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; DISEASE ASSOCIATION; ENZYME PHOSPHORYLATION; HEART CONTRACTION; HEART MUSCLE CELL; HYPERTENSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VASCULAR RING; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; ANIMAL; CHO CELL LINE; CRICETULUS; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; HAMSTER; HEART; METABOLISM; PHOSPHORYLATION; RAT; SMOOTH MUSCLE FIBER; SPRAGUE DAWLEY RAT;

ADRENERGIC ALPHA-1 RECEPTOR AGONISTS; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; AMYLOID BETA-PEPTIDES; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART; MALE; MICE; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; MYOCYTES, SMOOTH MUSCLE; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; SIGNAL TRANSDUCTION;

EID: 84886404910     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.01348     Document Type: Article

References (31)

1. Chiang PK, Lam MA, Luo Y. The many faces of amyloid β in Alzheimer's disease. Curr Mol Med. 2008;8:580-584.
2. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362:329-344.
3. Zhang H, Ma Q, Zhang YW, Xu H. Proteolytic processing of Alzheimer's β-amyloid precursor protein. J Neurochem. 2012;120(suppl 1):9-21.
4. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem. 2008;283:29615-29619.
5. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353-356.
6. Millucci L, Ghezzi L, Bernardini G, Santucci A. Conformations and biological activities of amyloid β peptide 25-35. Curr Protein Pept Sci. 2010;11:54-67.
7. Stepanichev MY, Zdobnova IM, Zarubenko II, Lazareva NA, Gulyaeva NV. Studies of the effects of central administration of β-amyloid peptide (25-35): pathomorphological changes in the Hippocampus and impairment of spatial memory. Neurosci Behav Physiol. 2006;36:101-106.
8. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW. Structure-activity analyses of β-amyloid peptides: contributions of the β 25-35 region to aggregation and neurotoxicity. J Neurochem. 1995;64:253-265.
9. Lorton D, Kocsis JM, King L, Madden K, Brunden KR. β-Amyloid induces increased release of interleukin-1 β from lipopolysaccharideactivated human monocytes. J Neuroimmunol. 1996;67:21-29.
10. de la Torre JC. Is alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 2004;3:184-190.
11. Smith EE, Greenberg SM. β-Amyloid, blood vessels, and brain function. Stroke. 2009;40:2601-2606.
12. Thomas T, Sutton ET, Hellermann A, Price JM. β-Amyloid-induced coronary artery vasoactivity and endothelial damage. J Cardiovasc Pharmacol. 1997;30:517-522.
13. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. β-Amyloid- mediated vasoactivity and vascular endothelial damage. Nature. 1996;380:168-171.
14. Elias MF, Davey A. Midlife blood pressure, amyloid-β, and risk for Alzheimer disease: one more reason to treat hypertension. Hypertension. 2012;59:771-772.
15. Carnevale D, Mascio G, Ajmone-Cat MA, D'Andrea I, Cifelli G, Madonna M, Cocozza G, Frati A, Carullo P, Carnevale L, Alleva E, Branchi I, Lembo G, Minghetti L. Role of neuroinflammation in hypertension- induced brain amyloid pathology. Neurobiol Aging. 2012;33:205. e19-205.e29.
16. Wenzel K, Haase H, Wallukat G, et al. Potential relevance of α(1)- adrenergic receptor autoantibodies in refractory hypertension. PLoS One. 2008;3:e3742.
17. Karczewski P, Pohlmann A, Wagenhaus B, Wisbrun N, Hempel P, Lemke B, Kunze R, Niendorf T, Bimmler M. Antibodies to the α1-adrenergic receptor cause vascular impairments in rat brain as demonstrated by magnetic resonance angiography. PLoS One. 2012;7:e41602.
18. Gupta A, Décaillot FM, Gomes I, Tkalych O, Heimann AS, Ferro ES, Devi LA. Conformation state-sensitive antibodies to G-protein-coupled receptors. J Biol Chem. 2007;282:5116-5124.
19. Lamounier-Zepter V, Ehrhart-Bornstein M, Karczewski P, Haase H, Bornstein SR, Morano I. Human adipocytes attenuate cardiomyocyte contraction: characterization of an adipocyte-derived negative inotropic activity. FASEB J. 2006;20:1653-1659.
20. Fésüs G, Dubrovska G, Gorzelniak K, Kluge R, Huang Y, Luft FC, Gollasch M. Adiponectin is a novel humoral vasodilator. Cardiovasc Res. 2007;75:719-727.
21. de la Torre JC. Vascular basis of alzheimer's pathogenesis. Ann N Y Acad Sci. 2002;977:196-215.
22. Iadecola C, Park L, Capone C. Threats to the mind: aging, amyloid, and hypertension. Stroke. 2009;40(3 suppl):S40-S44.
23. Chi X, Sutton ET, Thomas T, Price JM. The protective effect of K+ channel openers on β-amyloid induced cerebrovascular endothelial dysfunction. Neurol Res. 1999;21:345-351.
24. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci. 2004;5:347-360.
25. Silverberg GD, Miller MC, Messier AA, Majmudar S, Machan JT, Donahue JE, Stopa EG, Johanson CE. Amyloid deposition and influx transporter expression at the blood-brain barrier increase in normal aging. J Neuropathol Exp Neurol. 2010;69:98-108.
26. Van De Parre TJ, Guns PJ, Fransen P, Martinet W, Bult H, Herman AG, De Meyer GR. Attenuated atherogenesis in apolipoprotein e-deficient mice lacking amyloid precursor protein. Atherosclerosis. 2011;216:54-58.
27. Shah NS, Vidal JS, Masaki K, Petrovitch H, Ross GW, Tilley C, DeMattos RB, Tracy RP, White LR, Launer LJ. Midlife blood pressure, plasma β-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study. Hypertension. 2012;59:780-786.
28. Carnevale D, Mascio G, D'Andrea I, Fardella V, Bell RD, Branchi I, Pallante F, Zlokovic B, Yan SS, Lembo G. Hypertension induces brain β-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension. 2012;60:188-197.
29. Tanila H. Wading pools, fading memories-place navigation in transgenic mouse models of Alzheimer's disease. Front Aging Neurosci. 2012;4:11.
30. Saido TC. Alzheimer's disease as proteolytic disorders: anabolism and catabolism of β-amyloid. Neurobiol Aging. 1998;19(1 suppl):S69-S75.
31. Ma B, Nussinov R. Stabilities and conformations of Alzheimer's β-amyloid peptide oligomers (Aβ 16-22, Aβ 16-35, and Aβ 10-35): sequence effects. Proc Natl Acad Sci U S A. 2002;99:14126-14131.